Kaposi's sarcoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Hudakarman (talk | contribs) (→Gender) |
||
| (26 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Kaposi's sarcoma}} | {{Kaposi's sarcoma}} | ||
{{CMG}}; {{AE}} {{Rim}} | {{CMG}}; {{AE}} {{Rim}}{{ADS}} {{Hudakarman}} | ||
==Overview== | ==Overview== | ||
In the United States, the age-adjusted [[prevalence]] of Kaposi sarcoma is 8.1 per 100,000. The [[age]]-adjusted [[incidence]] of Kaposi sarcoma was 0.64 per 100,000 persons in the United States in 2011. [[Male]] are more commonly affected by Kaposi's sarcoma than [[female]]. The [[male]] to [[female]] ratio is approximately 10-15:1. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
=== | ===Incidence=== | ||
* In 2011, the [[age]]-adjusted [[incidence]] of Kaposi sarcoma was 0.64 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | |||
* Shown below is an image depicting the [[incidence]] of Kaposi sarcoma versus all types of [[cancers]] in the United States from 1975 to 2011. | |||
[[Image:Incidence of all cancer sites vs Kaposi sarcoma in USA between 1975-2011.PNG|400px|Incidence of Kaposi sarcoma versus all types of cancers in the United States from 1975 to 2011]] | |||
=== | ===Prevalence=== | ||
* In | * In the United States, the age-adjusted [[prevalence]] of Kaposi sarcoma is 8.1 per 100,000 in 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
===Age=== | ===Age=== | ||
*[[AIDS]]-related Kaposi sarcoma usually occurs in young to middle [[aged]] [[patients]] aged 20-54 years.<ref name="pmid25139791">{{cite journal |vauthors=Luu HN, Amirian ES, Chiao EY, Scheurer ME |title=Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men |journal=Cancer Med |volume=3 |issue=6 |pages=1635–43 |date=December 2014 |pmid=25139791 |pmc=4298390 |doi=10.1002/cam4.312 |url=}}</ref> | |||
* | *Classic Kaposi sarcoma generally seen in [[patients]] aged 50-70 years.<ref name="pmid26035321">{{cite journal |vauthors=Labo N, Miley W, Benson CA, Campbell TB, Whitby D |title=Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy |journal=AIDS |volume=29 |issue=10 |pages=1217–25 |date=June 2015 |pmid=26035321 |doi=10.1097/QAD.0000000000000682 |url=}}</ref> | ||
*African Kaposi sarcoma occurs in younger [[age]] around 35-40 years old.<ref name="pmid21377267">{{cite journal |vauthors=Uldrick TS, Whitby D |title=Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma |journal=Cancer Lett. |volume=305 |issue=2 |pages=150–62 |date=June 2011 |pmid=21377267 |doi=10.1016/j.canlet.2011.02.006 |url=}}</ref> | |||
===Gender=== | ===Gender=== | ||
*[[AIDS]]-related Kaposi sarcoma usually occurs in [[homosexual]] [[males]], bisexual men, and in the [[female]] [[sexual]] partners of bisexual men.<ref name="pmid21377267" /><ref name="pmid17146369">{{cite journal |vauthors=Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, Gwanzura L, Campbell TB |title=Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe |journal=J. Acquir. Immune Defic. Syndr. |volume=44 |issue=3 |pages=306–8 |date=March 2007 |pmid=17146369 |doi=10.1097/QAI.0b013e31802c83d9 |url=}}</ref><ref name="pmid6283973">{{cite journal |vauthors=Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, Spigland I, Kim KS, Zolla-Pazner S |title=Disseminated Kaposi's sarcoma in homosexual men |journal=Ann. Intern. Med. |volume=96 |issue=6 Pt 1 |pages=693–700 |date=June 1982 |pmid=6283973 |doi=10.7326/0003-4819-96-6-693 |url=}}</ref> | |||
* | *African Kaposi sarcoma seen in [[heterosexual]] [[men]] and [[women]] equally. | ||
* | *[[Male]] are more commonly affected by Kaposi's sarcoma than [[female]]. The [[male]] to [[female]] ratio is approximately 10-15:1.<ref name="pmid18665016">{{cite journal |vauthors=Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN |title=Awareness of Kaposi's sarcoma-associated herpesvirus among men who have sex with men |journal=Sex Transm Dis |volume=35 |issue=12 |pages=1011–4 |date=December 2008 |pmid=18665016 |pmc=2593118 |doi=10.1097/OLQ.0b013e318182c91f |url=}}</ref> | ||
* | |||
===Race=== | ===Race=== | ||
* Shown below is a table depicting the [[age]]-adjusted [[prevalence]] of Kaposi sarcoma by [[race]] in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | |||
* Shown below is a table depicting the age adjusted prevalence of Kaposi sarcoma by race in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
|- | |- | ||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic''' | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''All Races''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Asian/Pacific Islander''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Hispanic''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |8.1 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |8 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 12.4 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |2 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |11.1 per 100,000 | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:HIV/AIDS]] | [[Category:HIV/AIDS]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Vascular medicine]] | |||
[[Category:Surgery]] | |||
Latest revision as of 14:13, 10 October 2019
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma epidemiology and demographics |
|
Risk calculators and risk factors for Kaposi's sarcoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]Amandeep Singh M.D.[3] Huda A. Karman, M.D.
Overview
In the United States, the age-adjusted prevalence of Kaposi sarcoma is 8.1 per 100,000. The age-adjusted incidence of Kaposi sarcoma was 0.64 per 100,000 persons in the United States in 2011. Male are more commonly affected by Kaposi's sarcoma than female. The male to female ratio is approximately 10-15:1.
Epidemiology and Demographics
Incidence
- In 2011, the age-adjusted incidence of Kaposi sarcoma was 0.64 per 100,000 persons in the United States.[1]
- Shown below is an image depicting the incidence of Kaposi sarcoma versus all types of cancers in the United States from 1975 to 2011.
Prevalence
- In the United States, the age-adjusted prevalence of Kaposi sarcoma is 8.1 per 100,000 in 2011.[1]
Age
- AIDS-related Kaposi sarcoma usually occurs in young to middle aged patients aged 20-54 years.[2]
- Classic Kaposi sarcoma generally seen in patients aged 50-70 years.[3]
- African Kaposi sarcoma occurs in younger age around 35-40 years old.[4]
Gender
- AIDS-related Kaposi sarcoma usually occurs in homosexual males, bisexual men, and in the female sexual partners of bisexual men.[4][5][6]
- African Kaposi sarcoma seen in heterosexual men and women equally.
- Male are more commonly affected by Kaposi's sarcoma than female. The male to female ratio is approximately 10-15:1.[7]
Race
- Shown below is a table depicting the age-adjusted prevalence of Kaposi sarcoma by race in 2011 in the United States.[1]
| All Races | White | Black | Asian/Pacific Islander | Hispanic | |
| Age-adjusted prevalence | 8.1 per 100,000 | 8 per 100,000 | 12.4 per 100,000 | 2 per 100,000 | 11.1 per 100,000 |
References
- ↑ 1.0 1.1 1.2 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
- ↑ Luu HN, Amirian ES, Chiao EY, Scheurer ME (December 2014). "Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men". Cancer Med. 3 (6): 1635–43. doi:10.1002/cam4.312. PMC 4298390. PMID 25139791.
- ↑ Labo N, Miley W, Benson CA, Campbell TB, Whitby D (June 2015). "Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy". AIDS. 29 (10): 1217–25. doi:10.1097/QAD.0000000000000682. PMID 26035321.
- ↑ 4.0 4.1 Uldrick TS, Whitby D (June 2011). "Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma". Cancer Lett. 305 (2): 150–62. doi:10.1016/j.canlet.2011.02.006. PMID 21377267.
- ↑ Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, Gwanzura L, Campbell TB (March 2007). "Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe". J. Acquir. Immune Defic. Syndr. 44 (3): 306–8. doi:10.1097/QAI.0b013e31802c83d9. PMID 17146369.
- ↑ Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, Spigland I, Kim KS, Zolla-Pazner S (June 1982). "Disseminated Kaposi's sarcoma in homosexual men". Ann. Intern. Med. 96 (6 Pt 1): 693–700. doi:10.7326/0003-4819-96-6-693. PMID 6283973.
- ↑ Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN (December 2008). "Awareness of Kaposi's sarcoma-associated herpesvirus among men who have sex with men". Sex Transm Dis. 35 (12): 1011–4. doi:10.1097/OLQ.0b013e318182c91f. PMC 2593118. PMID 18665016.